MedDataX Logo

Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children

NCT ID: NCT01195779

Last Updated: 2020-10-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2011-03-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2584786A in healthy children 6 to 35 months of age.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza Influenza Vaccines

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GSK2584786A vaccine 1 dose of Formulation A1 Group

Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.

Group Type EXPERIMENTAL

GSK Bio's influenza vaccine GSK2584786A, different formulations

Intervention Type BIOLOGICAL

Intramuscular injections

GSK2584786A vaccine 2 doses of Formulation A1 Group

Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.

Group Type EXPERIMENTAL

GSK Bio's influenza vaccine GSK2584786A, different formulations

Intervention Type BIOLOGICAL

Intramuscular injections

GSK2584786A vaccine 1 dose of Formulation A2 Group

Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.

Group Type EXPERIMENTAL

GSK Bio's influenza vaccine GSK2584786A, different formulations

Intervention Type BIOLOGICAL

Intramuscular injections

GSK2584786A vaccine 2 doses of Formulation A2 Group

Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.

Group Type EXPERIMENTAL

GSK Bio's influenza vaccine GSK2584786A, different formulations

Intervention Type BIOLOGICAL

Intramuscular injections

GSK2584786A vaccine 1 dose of Formulation A3 Group

Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.

Group Type EXPERIMENTAL

GSK Bio's influenza vaccine GSK2584786A, different formulations

Intervention Type BIOLOGICAL

Intramuscular injections

GSK2584786A vaccine 2 doses of Formulation A3 Group

Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.

Group Type EXPERIMENTAL

GSK Bio's influenza vaccine GSK2584786A, different formulations

Intervention Type BIOLOGICAL

Intramuscular injections

GSK2584786A vaccine 1 dose of Formulation B1 Group

Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.

Group Type EXPERIMENTAL

GSK Bio's influenza vaccine GSK2584786A, different formulations

Intervention Type BIOLOGICAL

Intramuscular injections

GSK2584786A vaccine 2 doses of Formulation B1 Group

Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.

Group Type EXPERIMENTAL

GSK Bio's influenza vaccine GSK2584786A, different formulations

Intervention Type BIOLOGICAL

Intramuscular injections

GSK2584786A vaccine 1 dose of Formulation B2 Group

Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.

Group Type EXPERIMENTAL

GSK Bio's influenza vaccine GSK2584786A, different formulations

Intervention Type BIOLOGICAL

Intramuscular injections

GSK2584786A vaccine 2 doses of Formulation B2 Group

Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.

Group Type EXPERIMENTAL

GSK Bio's influenza vaccine GSK2584786A, different formulations

Intervention Type BIOLOGICAL

Intramuscular injections

GSK2584786A vaccine 1 dose of Formulation B3 Group

Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.

Group Type EXPERIMENTAL

GSK Bio's influenza vaccine GSK2584786A, different formulations

Intervention Type BIOLOGICAL

Intramuscular injections

GSK2584786A vaccine 2 doses of Formulation B3 Group

Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.

Group Type EXPERIMENTAL

GSK Bio's influenza vaccine GSK2584786A, different formulations

Intervention Type BIOLOGICAL

Intramuscular injections

GSK2321138A vaccine Group

Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).

Group Type EXPERIMENTAL

GSK Bio's influenza vaccine GSK2321138A

Intervention Type BIOLOGICAL

Intramuscular injections

Fluarix Group

Subjects received 2 doses of Fluarix Vaccine.

Group Type ACTIVE_COMPARATOR

Fluarix™

Intervention Type BIOLOGICAL

Intramuscular injections

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GSK Bio's influenza vaccine GSK2584786A, different formulations

Intramuscular injections

Intervention Type BIOLOGICAL

GSK Bio's influenza vaccine GSK2321138A

Intramuscular injections

Intervention Type BIOLOGICAL

Fluarix™

Intramuscular injections

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All subjects must satisfy ALL the following criteria at study entry:

* Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) \[LAR(s)\] can and will comply with the requirements of the protocol
* Children, male or female between, and including, 6 and 35 months of age at the time of the first vaccination.
* Written informed consent obtained from the parent(s)/LAR(s) of the subject.
* Healthy subjects as established by medical history and clinical examination before entering into the study.
* Age appropriate scheduled childhood vaccinations completed to the best of parent(s)/LAR(s) knowledge.
* Born after gestation period of 36 to 42 weeks inclusive

Exclusion Criteria

The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:

* Child in "care"
* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
* Prior receipt of any influenza vaccination or planned administration during the study period.
* Planned administration of any vaccine 30 days prior and 30 days after any study vaccine administration.
* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
* A family history of congenital or hereditary immunodeficiency.
* A family history of febrile seizures or/and epilepsy
* Any known or suspected allergy to any constituent of influenza or routine paediatric vaccines, a history of severe adverse reaction to any previous vaccination; or a history of anaphylactic-type reaction to any constituent of influenza vaccine.
* History of any progressive neurological disorders or seizures.
* Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history or physical examination.
* Acute disease and/or fever at the time of enrolment:
* \- Fever is defined as temperature ≥ 37.5°C on oral, axillary or tympanic setting, or ≥38.0°C on rectal setting.
* Subjects with a minor illness without fever might be enrolled at the discretion of the investigator.
* Administration of immunoglobulins and/or any blood products within the 3 month preceding the first dose of study vaccine or planned administration during the study period.
* Any condition which, in the opinion of the investigator, render the subject unfit for participation in the study.
Minimum Eligible Age

6 Months

Maximum Eligible Age

35 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Seville, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-020312-12

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

114294

Identifier Type: -

Identifier Source: org_study_id